We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
51
PUT
Arcus Biosciences
RCUS
$3.33B
$6.74M 0.55%
245,500
– –
KOD icon
52
CALL
Kodiak Sciences
KOD
$2.5B
$6.72M 0.54%
+72,300
New +$6.94M
SCPH
53
DELISTED
scPharmaceuticals
SCPH
$6.69M 0.54%
1,095,024
-213,675
-16% -$1.29M
KYNB
54
CALL
Kyntra Bio
KYNB
$27.4M
$6.66M 0.54%
+10,000
New +$5.76M
CLVS
55
DELISTED
Clovis Oncology, Inc.
CLVS
$6.55M 0.53%
1,129,473
+450,000
+66% +$2.64M
RLMD icon
56
CALL
Relmada Therapeutics
RLMD
$540M
$6.51M 0.53%
203,400
+5,800
+3% +$201K
CCXI
57
DELISTED
ChemoCentryx, Inc.
CCXI
$6.31M 0.51%
+471,376
New +$11.6M
OCUL icon
58
Ocular Therapeutix
OCUL
$1.83B
$5.95M 0.48%
419,573
– –
TARA icon
59
Protara Therapeutics
TARA
$214M
$5.7M 0.46%
584,804
-64,738
-10% -$733K
VSTM icon
60
Verastem
VSTM
$528M
$5.67M 0.46%
116,200
-108,333
-48% -$4.52M
VINC
61
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$5.54M 0.45%
21,337
-597
-3% -$182K
CMMB
62
Chemomab Therapeutics
CMMB
$10.7M
$5.53M 0.45%
+72,634
New +$7.1M
STTK icon
63
Shattuck Labs
STTK
$646M
$5.52M 0.45%
190,330
– –
GILD icon
64
CALL
Gilead Sciences
GILD
$165B
$5.51M 0.45%
80,000
-363,600
-82% -$24.3M
IOVA icon
65
PUT
Iovance Biotherapeutics
IOVA
$2.04B
$5.2M 0.42%
200,000
– –
KYNB
66
PUT
Kyntra Bio
KYNB
$27.4M
$5.16M 0.42%
7,752
-4,248
-35% -$2.45M
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.13M 0.42%
54,815
+54,212
+8,990% +$4.99M
ACAD icon
68
Acadia Pharmaceuticals
ACAD
$4.51B
$5.12M 0.41%
209,866
+203,858
+3,393% +$4.6M
LYRA
69
DELISTED
LYRA THERAPEUTICS INC
LYRA
$5.02M 0.41%
12,494
-3,121
-20% -$1.42M
JETS icon
70
CALL
US Global Jets ETF
JETS
$768M
$4.84M 0.39%
+200,000
New +$5.22M
FNCH
71
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$4.57M 0.37%
10,833
+5,833
+117% +$2.52M
IOVA icon
72
Iovance Biotherapeutics
IOVA
$2.04B
$4.55M 0.37%
+175,000
New +$4.55M
STSA
73
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$4.54M 0.37%
644,056
-32,238
-5% -$174K
OVID icon
74
Ovid Therapeutics
OVID
$427M
$4.4M 0.36%
1,124,872
– –
CHAQ.U
75
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.37M 0.35%
400,000
– –
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.